Project Echo: Tele-mentoring to Manage Immune-Related Adverse Events in Patients Receiving Cancer Immunotherapies: Hepatobiliary Toxicities with Immune Checkpoint Inhibitors - March 21, 2023

This page is for learners who attended the March 21, 2023, virtual session to claim credit.

Claiming Credit

Thank you for participating in this program. Once logged in, please click on "Take Course" on the right-hand side and your enrollment will be recorded. You will be prompted to complete the posttest, evaluation and claim your credit on the following page.
 
 
Immunotherapies have yielded impressive clinical benefits in a growing number of cancers, and in many cases, they have surpassed the efficacy of existing therapies. Immunotherapy usage is expected to increase in cancer care with the rapid approval of several new drugs and expanded indications for existing drugs in this class. However, the expanding armamentarium of immunotherapies available to treat patients with cancer poses a challenge to community clinicians with respect to integrating this new class of agents into practice. Community cancer programs need guidance regard the practical issues that cancer programs must navigate to provide immunotherapy safely and effectively in their own communities.

Target Audience

The target audience for this initiative includes oncologists, oncology advanced practice providers (nurse practitioners, physician assistants), oncology pharmacists, oncology nurses, and other healthcare professionals (HCPs) involved in treating patients with cancer immunotherapies.

Learning Objectives

   At the end of this educational activity, participants will be able to: 
  • Apply evidence-based practices for the monitoring and management of irAEs in patients receiving cancer immunotherapies         
  • Improve coordination and communication with non-oncology specialists and with patients/caregivers to manage irAEs in patients receiving cancer immunotherapies
  • Review strategies for providing equitable care for underserved patients receiving cancer immunotherapies

Additional Information

AttachmentSize
PDF icon BU_ProjectEchoCE_Statement.pdf168.71 KB
Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™

    Boston University Chobanian & Avedisian School of Medicine designates this Enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • 1.00 ANCC
  • 1.00 Participation
Course opens: 
03/21/2023
Course expires: 
03/20/2024
Rating: 
0

In support of improving patient care, this activity has been planned and implemented by Boston University Chobanian & Avedisian School of Medicine and the Association of Community Cancer Centers. Boston University Chobanian & Avedisian School of Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Boston University Chobanian & Avedisian School of Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity

Contact Hours: 1.0, of which 1.0 is pharmacology credit worthy

 

The University of Rhode Island College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.  This is an application-based educational activity. Pharmacists will receive 1.0 contact hour (0.10 CEUS) for the educational activity. No partial credit is available. 

UNIVERSAL ACTIVITY NUMBERS (UAN) 0060-9999-22-085-L01-P

Please see the additional information tab in the Overview section for directions on how to claim credit.

Available Credit

  • 1.00 AMA PRA Category 1 Credit™

    Boston University Chobanian & Avedisian School of Medicine designates this Enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • 1.00 ANCC
  • 1.00 Participation
Please login or register to take this course.

Please click on "Take Course" above to begin the credit claiming process.